<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962855</url>
  </required_header>
  <id_info>
    <org_study_id>UMMS-TPRA-01</org_study_id>
    <nct_id>NCT03962855</nct_id>
  </id_info>
  <brief_title>Thromboxane Receptor Antagonist to Improve Endothelial Cell Function</brief_title>
  <acronym>TRAP</acronym>
  <official_title>The Thromboxane Receptor Antagonist to Blunt the Effects of Non-Platelet Thromboxane Generation and Improve Endothelial Cell Function (TRAP) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Rade</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether addition of the thromboxane receptor antagonist to chronic
      aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation
      in patients with established cardiovascular disease. Half of participants will receive
      ifetroban and the other half will receive matchcing placebo for the 4 week study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thromboxane is a prostaglandin produced in healthy individuals mainly in platelets, where it
      mediates platelet activation and vasoconstriction via binding to cellular
      thromboxane-prostanoid (TP) receptors. The cardioprotective effect of aspirin is due to
      suppression of platelet thromboxane generation and reactivity. Unfortunately 25-50% of
      patients with cardiovascular disease taking ASA continue to generate thromboxane from
      non-platelet sources, which significantly increases their risk of atherothrombosis and death.
      Evidence suggests that oxidative stress is a potent stimulus for thromboxane generation in
      endothelial cells that involves autocrine/paracrine signaling through the TP receptor. This
      clinical trial addresses the central hypothesis that vascular endothelial cells under
      oxidative stress are a major source of non-platelet thromboxane generation in patients with
      cardiovascular disease and that antagonism of the TP receptor will suppress its formation and
      improve endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, prospectively randomized, double-blinded, placebo-controlled clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in Reactive Hyperemia Index (RHI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial vasoractivity</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in Percent flow-mediated vasodilation (FMD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-platelet thromboxane generation</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in urine 11-dehydrothromboxane B2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in urine 8-isoPGF2a</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal Prostanoid Excretion</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in urine TXB2, 6-ketoPGF1α and the ratio of TXB2 to 6-ketoPGF1α,</description>
  </other_outcome>
  <other_outcome>
    <measure>Prostacyclin Generation</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in urine 2,3-dinor-6-ketoPGF1α and ratio of 11-dhTXB2 to 2,3-dinor-6-ketoPGF1α</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in hs-CRP and ICAM-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Coagulation Markers</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in soluble tissue factor and activated protein C</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal Function</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in eGFR</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in NT pro-BNP</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Vascular Dilation</condition>
  <arm_group>
    <arm_group_label>Ifetroban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered once daily for a minimum of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifetroban Sodium</intervention_name>
    <description>Ifetroban sodium 250 mg capsule once daily for 4 weeks</description>
    <arm_group_label>Ifetroban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo arm to match Ifetroban Sodium once daily for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥18 years of age with established cardiovascular disease

          -  Take 81 mg daily of aspirin as part of their daily medical regimen

          -  Urine thromboxane B2 metabolites &gt;1500 pg/mg creatinine on screening.

          -  Able to provide written consent and comply with protocol-specific procedures.

        Exclusion Criteria:

          -  Chronic oral anticoagulation.

          -  ST segment myocardial infarction within 1 month.

          -  Cardiac surgery within 1 month.

          -  Ongoing uncontrolled severe inflammatory condition.

          -  Pregnant or lactating.

          -  Ifetroban or aspirin sensitivity

          -  Inability to perform vascular testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J Rade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Papalia, BSN</last_name>
    <phone>508-856-1014</phone>
    <email>Susan.Papalia@umassmed.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey J Rade, MD</last_name>
      <phone>774-441-6310</phone>
      <email>jeffrey.rade@umassmed.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Papalia, RN</last_name>
      <phone>508-856-1014</phone>
      <email>susan.papalia@umassmed.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffreyt J Rade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Jeffrey Rade</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

